Cel Sci Corporation (CVM)

[Fosco1]

Yes very true.

While success/failure of this clinical trial will be assessed using statistics in deaths counts in both arms ("Primary outcome measure")

QoL is indeed a secondary outcome measure : For the patients QoL will NOT be only "interesting", having a better QoL due to MK is a real benefit and also a motivation to be treated longer, to live longer that should be reflected in primary outcome measure. But statistics also will be used to measure QoL improvements in both arms (patients had to fill a questionnaire that will be processed/compared using statistical methods)